Chiun Hsu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2932311/publications.pdf

Version: 2024-02-01

204 papers	11,550 citations	47 h-index	100 g-index
		47006	32842
211 all docs	211 docs citations	211 times ranked	13684 citing authors

#	Article	IF	Citations
1	Fully digital problem-based learning for undergraduate medical students during the COVID-19 period: Practical considerations. Journal of the Formosan Medical Association, 2022, 121, 2130-2134.	1.7	8
2	Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. Cancers, 2022, 14, 294.	3.7	24
3	AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, TPS488-TPS488.	1.6	0
4	Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. British Journal of Cancer, 2022, 126, 1806-1814.	6.4	11
5	Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma. Frontiers in Immunology, 2022, 13, 870406.	4.8	0
6	Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208.. Journal of Clinical Oncology, 2022, 40, e16181-e16181.	1.6	0
7	AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, TPS4172-TPS4172.	1.6	1
8	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2021, 120, 1051-1060.	1.7	72
9	Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110311.	3.2	19
10	Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1 (ALK-1) antibody, and nivolumab in patients with metastatic hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2021, 39, 326-326.	1.6	5
11	Spectrum of cancer patients receiving renal biopsy. Journal of the Formosan Medical Association, 2021, 121, 152-152.	1.7	0
12	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. Journal of the Chinese Medical Association, 2021, 84, 144-150.	1.4	8
13	Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages. , 2021, 9, e001657.		63
14	Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 346-359.	7.7	70
15	Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Seminars in Liver Disease, 2021, 41, 263-276.	3.6	14
16	Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma. Diagnostics, 2021, 11, 1340.	2.6	6
17	Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma. Cells, 2021, 10, 1698.	4.1	5
18	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 809-822.	3.7	17

#	Article	IF	Citations
19	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. Cancers, 2021, 13, 5142.	3.7	2
20	Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials. Cancers, 2021, 13, 4962.	3.7	3
21	Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study. , 2021, 59, .		1
22	360â€…Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC). , 2021, 9, A387-A387.		2
23	Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma. Journal of Cancer Research and Practice, 2021, 8, 127.	0.2	2
24	Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. Journal of the Formosan Medical Association, 2020, 119, 335-344.	1.7	8
25	Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Journal of the Formosan Medical Association, 2020, 119, 97-105.	1.7	3
26	A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinomaâ€“TCOG T1211 study. European Journal of Cancer, 2020, 124, 123-130.	2.8	11
27	Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study. Oncologist, 2020, 25, e1921-e1929.	3.7	5
28	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. JAMA Oncology, 2020, 6, e204564.	7.1	746
29	Novel systemic therapy for hepatocellular carcinoma. Hepatology International, 2020, 14, 638-651.	4.2	15
30	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. Journal of the Formosan Medical Association, 2020, 120, 1581-1590.	1.7	4
31	Multicentre, phase II study of gemcitabine and Sâ€1 in patients with advanced biliary tract cancer: TG1308 study. Liver International, 2020, 40, 2535-2543.	3.9	7
32	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOSâ€“ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Annals of Oncology, 2020, 31, 334-351.	1.2	138
33	An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. Oncologist, 2020, 25, e782-e788.	3.7	7
34	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319.	3.7	310
35	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. Oncologist, 2020, 25, e1280-e1285.	3.7	14
36	Pembrolizumab for the treatment of programmed deathâ€“ligand 1â€'positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTEâ€028 study. Cancer, 2020, 126, 3021-3030.	4.1	97

#	Article	IF	Citations
37	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.. Journal of Clinical Oncology, 2020, 38, 512-512.	1.6	31
38	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 155-171.	7.7	25
39	Early alphaâ€foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver International, 2019, 39, 2184-2189.	3.9	55
40	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 480-490.	7.7	57
41	Klothoâ€beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma. Liver International, 2019, 39, 1682-1691.	3.9	19
42	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2019, 13, 615-621.	3.0	5
43	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. Journal of Hepatology, 2019, 71, 543-552.	3.7	180
44	FRI-471-Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization. Journal of Hepatology, 2019, 70, e605-e606.	3.7	18
45	Position Statement on Atopic Dermatitis in Subâ€Saharan Africa: current status and roadmap. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2019-2028.	2.4	24
46	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. Journal of Clinical Oncology, 2019, 37, 4012-4012.	1.6	178
47	An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).. Journal of Clinical Oncology, 2019, 37, 4101-4101.	1.6	1
48	Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. Journal of Hepatology, 2018, 69, 286-292.	3.7	76
49	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2018, 117, 381-403.	1.7	92
50	Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ: British Medical Journal, 2018, 363, k4226.	2.3	362
51	Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Seminars in Liver Disease, 2018, 38, 379-388.	3.6	62
52	Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study. Journal of Hepatology, 2018, 68, S16.	3.7	11
53	Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.. Journal of Clinical Oncology, 2018, 36, 475-475.	1.6	39
54	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, The, 2017, 389, 2492-2502.	13.7	3,224

#	Article	IF	Citations
55	Epithelioid Trophoblastic Tumor Around an Abdominal Cesarean Scar: A Pathologic and Molecular Genetic Analysis. International Journal of Gynecological Pathology, 2017, 36, 562-567.	1.4	13
56	Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. European Radiology, 2017, 27, 3069-3079.	4.5	18
57	Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy. Chemical Science, 2017, 8, 6670-6678.	7.4	13
58	Lenalidomide as secondâ€line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. Alimentary Pharmacology and Therapeutics, 2017, 46, 722-730.	3.7	12
59	Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1â€“Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. Journal of Clinical Oncology, 2017, 35, 4050-4056.	1.6	335
60	Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. Journal of Clinical Oncology, 2017, 35, 4013-4013.	1.6	76
61	Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict efficacy of axitinib for treatment of advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2017, 35, e15656-e15656.	1.6	1
62	Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.. Journal of Clinical Oncology, 2017, 35, 226-226.	1.6	19
63	Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 93-103.	0.1	2
64	A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer.. Journal of Clinical Oncology, 2017, 35, 417-417.	1.6	1
65	Nivolumab bei Sorafenib-naiven und -behandelten Patienten mit fortgeschrittenem hepatozellulÃrem Karzinom (HCC) CheckMate 040 Studie. , 2017, 55, .		0
66	Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. Scientific Reports, 2016, 6, 25369.	3.3	21
67	Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer, 2016, 5, 128-138.	7.7	108
68	Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy. Radiology, 2016, 281, 454-464.	7.3	33
69	Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Clinical Cancer Research, 2016, 22, 2555-2564.	7.0	42
70	Cough With Bile. American Journal of Gastroenterology, 2016, 111, 313.	0.4	0
71	Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.. Journal of Clinical Oncology, 2016, 34, 4078-4078.	1.6	30
72	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 7275.	3.3	26

#	Article	IF	Citations
73	Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC).. Journal of Clinical Oncology, 2016, 34, 369-369.	1.6	0
74	Low-dose nab-paclitaxel-based combination chemotherapy in heavily-pretreated pancreatic or ampullary cancer patients: Taiwanese single-center case series.. Journal of Clinical Oncology, 2016, 34, e15695-e15695.	1.6	0
75	A Decade of Changes in Preferences for Life-Sustaining Treatments Among Terminally Ill Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1510-1518.	4.9	10
76	Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Research and Treatment, 2015, 47, 343-361.	3.0	75
77	Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide. Hepatology International, 2015, 9, 258-268.	4.2	13
78	Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer, 2015, 4, 96-105.	7.7	19
79	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Annals of Oncology, 2015, 26, 943-949.	1.2	130
80	The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. Oncologist, 2015, 20, 1051-1057.	3.7	13
81	Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. Oncotarget, 2015, 6, 27953-27965.	1.8	14
82	Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. Journal of Hepatocellular Carcinoma, 2014, 1, 85.	3.7	17
83	A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 5976-5985.	7.0	95
84	Reply. Hepatology, 2014, 60, 766-767.	7.3	0
85	Clinicopathological and prognostic significances of <scp>EGFR</scp>, <scp>KRAS</scp> and <scp>BRAF</scp> mutations in biliary tract carcinomas in <scp>T</scp>aiwan. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1119-1125.	2.8	28
86	Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. British Journal of Cancer, 2014, 111, 2067-2075.	6.4	37
87	H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 Pathway to Suppress Lung Cancer Metastasis. Cancer Research, 2014, 74, 7333-7343.	0.9	58
88	Potential synergistic antiâ€tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 2021-2031.	2.8	12
89	Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology, 2014, 59, 2092-2100.	7.3	235
90	Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin. Molecular Cancer, 2014, 13, 2.	19.2	32

#	Article	IF	Citations
91	Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. Supportive Care in Cancer, 2014, 22, 1189-1197.	2.2	13
92	Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer Journal, 2014, 4, e220-e220.	6.2	43
93	Comparison of Characteristics and Transarterial Chemoembolization Outcomes in Patients with Unresectable Hepatocellular Carcinoma and Different Viral Etiologies. Journal of Vascular and Interventional Radiology, 2014, 25, 371-378.	0.5	10
94	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology, 2014, 87, 104-113.	1.9	28
95	Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma. World Journal of Gastroenterology, 2014, 20, 5060.	3.3	21
96	Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial.. Journal of Clinical Oncology, 2014, 32, 267-267.	1.6	0
97	The impact of diabetes mellitus on early cervical cancer in Î¯sia: A population-based cohort study.. Journal of Clinical Oncology, 2014, 32, e16501-e16501.	1.6	0
98	Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. European Journal of Cancer, 2013, 49, 3486-3496.	2.8	103
99	Clinical Trials in Hepatocellular Carcinoma: An Update. Liver Cancer, 2013, 2, 345-364.	7.7	58
100	Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients. Annals of Oncology, 2013, 24, 463-468.	1.2	32
101	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed antiâ€angiogenic therapy. Liver International, 2013, 33, 1413-1419.	3.9	15
102	Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. British Journal of Cancer, 2013, 108, 72-81.	6.4	160
103	Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study. Oncology, 2013, 85, 44-52.	1.9	46
104	14-3-3Îµ Overexpression Contributes to Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e57968.	2.5	57
105	Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway. PLoS ONE, 2013, 8, e66589.	2.5	11
106	KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial.. Journal of Clinical Oncology, 2013, 31, 4018-4018.	1.6	9
107	Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size. PLoS ONE, 2013, 8, e80276.	2.5	23
108	Survival of patients receiving radiofrequency ablation or ethanol injection for early-stage hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, e15043-e15043.	1.6	0

#	Article	IF	Citations
109	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. British Journal of Cancer, 2012, 107, 1672-1677.	6.4	24
110	Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma. Oncologist, 2012, 17, 856-862.	3.7	32
111	Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy. Oncologist, 2012, 17, 970-977.	3.7	9
112	Perspectives on The Design of Clinical Trials Combining Transarterial Chemoembolization and Molecular Targeted Therapy. Liver Cancer, 2012, 1, 168-176.	7.7	19
113	Phase II Study of Concomitant Thalidomide During Radiotherapy for Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, 817-825.	0.8	15
114	Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Journal of Hepatology, 2012, 56, 1097-1103.	3.7	91
115	Comparative microRNA detection from precursorâ€microRNAâ€transfected hepatocellular carcinoma cells by capillary electrophoresis with dualâ€color laserâ€induced fluorescence. Electrophoresis, 2012, 33, 2769-2776.	2.4	16
116	Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma. Oncology, 2012, 82, 59-66.	1.9	29
117	A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression. Oncology, 2012, 82, 275-289.	1.9	35
118	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. Gastric Cancer, 2012, 15, 265-280.	5.3	17
119	Authorâ€™s reply: Vitamin A and gastric cancer risk. Gastric Cancer, 2012, 15, 344-344.	5.3	16
120	A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2012, 30, 4103-4103.	1.6	6
121	The first two lines of chemotherapy for anthracycline-naÃ¯ve metastatic breast cancer: A comparative study of efficacy between anthracyclines and nonanthracyclines.. Journal of Clinical Oncology, 2012, 30, 1061-1061.	1.6	0
122	Increased Expression of 14-3-3Î² Promotes Tumor Progression and Predicts Extrahepatic Metastasis and Worse Survival in Hepatocellular Carcinoma. American Journal of Pathology, 2011, 179, 2698-2708.	3.8	39
123	End-of-life care for cancer patients in Taiwan. Journal of the Formosan Medical Association, 2011, 110, 799.	1.7	0
124	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. Journal of Hepatology, 2011, 55, 858-865.	3.7	114
125	Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis. Nuclear Medicine Communications, 2011, 32, 252-259.	1.1	3
126	Overexpression of 14-3-3Îµ predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology, 2011, 58, 705-711.	2.9	45

#	Article	IF	Citations
127	Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Research and Treatment, 2011, 130, 345-351.	2.5	98
128	Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials. Oncology, 2011, 81, 143-150.	1.9	15
129	High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy. Oncology, 2011, 81, 98-103.	1.9	19
130	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-regression approach.. Journal of Clinical Oncology, 2011, 29, 109-109.	1.6	1
131	Use of plasma angiogenesis-related factors to investigate the association of interleukin 8 and interleukin 6 levels with efficacy of sorafenib-based antiangiogenic therapy in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2011, 29, 199-199.	1.6	10
132	Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2011, 29, 79-79.	1.6	0
133	Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. Journal of Gastroenterology, 2010, 45, 794-807.	5.1	61
134	Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer, 2010, 10, 620.	2.6	4
135	Early alphaâ€fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer, 2010, 116, 4590-4596.	4.1	154
136	Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. Liver International, 2010, 30, 1427-1438.	3.9	35
137	Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 2010, 102, 981-986.	6.4	127
138	Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. Japanese Journal of Clinical Oncology, 2010, 40, 286-293.	1.3	27
139	Induction of DNA Damage-Inducible Gene GADD45Î² Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2010, 70, 9309-9318.	0.9	76
140	Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. Journal of Experimental and Clinical Medicine, 2010, 2, 93-103.	0.2	21
141	Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. Journal of Hepatology, 2010, 52, 889-894.	3.7	125
142	Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sciences, 2010, 86, 199-206.	4.3	33
143	Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials, 2010, 31, 55-61.	1.8	46
144	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Journal of Hepatology, 2010, 53, 126-131.	3.7	124

#	Article	IF	Citations
145	116 USING DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING (DCE-MRI) TO PREDICT TREATMENT OUTCOMES FOR ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PATIENTS WHO RECEIVED SORAFENIB PLUS TEGAFUR/URACIL THERAPY. Journal of Hepatology, 2010, 52, S52.	3.7	1
146	Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy.. Journal of Clinical Oncology, 2010, 28, 4063-4063.	1.6	3
147	Nuclear Overexpression of Mitotic Regulatory Proteins in Biliary Tract Cancer: Correlation with Clinicopathologic Features and Patient Survival. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 417-423.	2.5	24
148	Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Clinical Cancer Research, 2009, 15, 5820-5828.	7.0	35
149	Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway. Journal of Biological Chemistry, 2009, 284, 11121-11133.	3.4	79
150	Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy. Hepatology, 2009, 50, 654-655.	7.3	3
151	Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. Human Pathology, 2009, 40, 1384-1390.	2.0	27
152	The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. Journal of Hepatology, 2009, 50, 518-527.	3.7	42
153	Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. Expert Review of Clinical Pharmacology, 2009, 2, 129-136.	3.1	11
154	Treatment of Hepatocellular Carcinoma with Thalidomide: Assessment with Power Doppler Ultrasound. , 2009, , 277-286.		0
155	Induction chemotherapy followed by concurrent chemoradiotherapy with/without esophagectomy for locally advanced esophageal squamous cell carcinoma. Journal of Clinical Oncology, 2009, 27, e15526-e15526.	1.6	0
156	Lamivudine and Hepatitis B Reactivation. Annals of Internal Medicine, 2009, 151, 141.	3.9	0
157	Abstract A241: Searching for extracellular signalâ€regulated kinase (ERK)â€independent molecular targets of sorafenib in hepatocellular carcinoma (HCC). , 2009, , .		2
158	A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology, 2008, 47, 844-853.	7.3	277
159	Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. Leukemia, 2008, 22, 544-550.	7.2	53
160	Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers. Lung Cancer, 2008, 60, 92-97.	2.0	11
161	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment. Lung Cancer, 2008, 60, 215-221.	2.0	2
162	Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinomaâ€"A randomized phase II trial. Lung Cancer, 2008, 62, 334-343.	2.0	14

#	Article	IF	Citations
163	Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer. Pancreas, 2008, 37, 145-150.	1.1	55
164	Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. Anti-Cancer Drugs, 2007, 18, 703-708.	1.4	8
165	Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 389-394.	2.8	22
166	Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: a preliminary result. Liver International, 2007, 27, 516-528.	3.9	14
167	Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncology, 2007, 2, 199-210.	3.6	6
168	Weekly paclitaxel, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil plus leucovorin (weekly) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2007, 25, 15165-15165.	1.6	0
169	A phase II study of weekly low-dose paclitaxel plus 24-hour infusion of cisplatin as first-line chemotherapy for metastatic breast cancer (MBC). Journal of Clinical Oncology, 2007, 25, 1100-1100.	1.6	1
170	CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Letters, 2006, 235, 34-39.	7.2	48
171	Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 531-536.	2.8	7
172	Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 874-879.	2.8	9
173	Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Investigational New Drugs, 2006, 25, 77-84.	2.6	107
174	Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer, 2006, 107, 1873-1882.	4.1	54
175	Difference in the Incidence Trend of Nasopharyngeal and Oropharyngeal Carcinomas in Taiwan: Implication from Age-Period-Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 856-861.	2.5	65
176	Prognostic factors for patients with metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. Journal of Clinical Oncology, 2006, 24, 14583-14583.	1.6	0
177	Outcome of advanced gastric cancer patients with disseminated intravascular coagulation and bone marrow metastasis is improved by weekly 24-Hour infusional high-dose 5-fluorouracil and leucovorin (HDFL)-based chemotherapy. Journal of Clinical Oncology, 2006, 24, 14132-14132.	1.6	0
178	Predictors for toxicity profiles of weekly docetaxel in non-small cell lung cancers. Journal of Clinical Oncology, 2006, 24, 17153-17153.	1.6	0
179	Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head and Neck, 2005, 27, 1022-1027.	2.0	38
180	Significant Difference in the Trends of Female Breast Cancer Incidence Between Taiwanese and Caucasian Americans: Implications from Age-Period-Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1986-1990.	2.5	130

#	Article	IF	Citations
181	Effect of Thalidomide in Hepatocellular Carcinoma: Assessment with Power Doppler US and Analysis of Circulating Angiogenic Factors. Radiology, 2005, 235, 509-516.	7.3	26
182	Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer. Oncology, 2005, 69, 88-95.	1.9	19
183	Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials. Lung Cancer, 2005, 48, 275-280.	2.0	8
184	Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World Journal of Gastroenterology, 2005, 11, 5283.	3.3	18
185	Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. British Journal of Cancer, 2004, 90, 1715-1719.	6.4	39
186	Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines. British Journal of Cancer, 2004, 91, 1561-1565.	6.4	5
187	Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Quality of Life Research, 2004, 13, 257-262.	3.1	89
188	Comparison of the antitumor activity of thalidomide between hepatitis B (HBV)- and hepatitis C (HCV)-related hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2004, 22, 4198-4198.	1.6	0
189	Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Hepato-Gastroenterology, 2004, 51, 815-9.	0.5	6
190	Recent advances in non-surgical treatment for advanced hepatocellular carcinoma. Journal of the Formosan Medical Association, 2004, 103, 483-95.	1.7	19
191	Comparison of the antitumor activity of thalidomide between hepatitis B (HBV)- and hepatitis C (HCV)-related hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2004, 22, 4198-4198.	1.6	0
192	Survival-weighted health profile for long-term survivors of acute myelogenous leukemia. Quality of Life Research, 2003, 12, 503-517.	3.1	29
193	Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma. Oncology, 2003, 65, 242-249.	1.9	85
194	HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer, 2002, 94, 415-420.	4.1	42
195	Phase II trial combining paclitaxel with 24â€hour infusion cisplatin for chemotherapyâ€naÃ¯ve patients with locally advanced or metastatic breast carcinoma. Cancer, 2002, 95, 2044-2050.	4.1	10
196	Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. British Journal of Cancer, 2002, 86, 190-195.	6.4	24
197	A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. Anticancer Research, 2002, 22, 3621-7.	1.1	7
198	Comparison of MALT and non-MALT primary large cell lymphoma of the stomach. Cancer, 2001, 91, 49-56.	4.1	11

#	Article	IF	Citations
199	Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach. American Journal of Hematology, 2000, 64, 175-179.	4.1	35
200	Phosphine-induced oxidative damage in rats: attenuation by melatonin. Free Radical Biology and Medicine, 2000, 28, 636-642.	2.9	100
201	Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome. Journal of the Formosan Medical Association, 1999, 98, 157-64.	1.7	5
202	Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer. Anticancer Research, 1998, 18, 1267-72.	1.1	6
203	MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer. Journal of the Formosan Medical Association, 1997, 96, 185-8.	1.7	4
204	Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 517-536.	3.7	0